<div id="readability-page-1"><div>Assertio Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRTFormer Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick &amp; Foti, LLC (“KSF”) are investigating the proposed sale of Assertio Holdings, Inc. (NasdaqCM: ASRT) to Garda Therapeutics. Under the terms of the proposed transaction, shareholders of Assertio will receive $18.00 per share in cash and a contingent value right. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-asrt/ to learn more.Please note that the transaction is structured as a tender offer, such that time may be of the essence.To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MTk4NzY2NzZyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MTk4NzY2NzZyMQ"/>Kahn Swick &amp; Foti, LLC Lewis Kahn, Managing Partner lewis.kahn@ksfcounsel.com 855-768-1857 1100 Poydras St., Suite 960 New Orleans, LA 70163View source version on businesswire.com: https://www.businesswire.com/news/home/20260519876676/en/</div></div>

ASRT

Kahn Swick & Foti, LLC 正在调查 Assertio Holdings, Inc. (ASRT) 拟议出售给 Garda Therapeutics 的事宜，股东将获得每股 18.00 美元。该公司旨在评估这一价格的合理性及其形成过程，质疑是否低估了该公司。感兴趣的各方可以联系 KSF 获取更多信息

Assertio 投资者警示：Kahn Swick & Foti, LLC 正在调查拟议出售 Assertio Holdings, Inc. - ASRT 的价格和流程是否合理